www.rybelsus.com
Open in
urlscan Pro
72.3.137.119
Public Scan
Submitted URL: http://email.mail.veeva.novonordisk.com/c/eJx8kU9z0zAQxT-NfItHWsVWfPDBrROmhQMUMpQTI0ubWMWWjP448O0ZhZLpiT2-_e2fN-9580EOOLVE3BGAxTudVHzQBI...
Effective URL: https://www.rybelsus.com/terms-and-conditions.html?utm_medium=email&utm_source=RTE&utm_campaign=successfulstarts&utm_cont...
Submission: On November 20 via manual from US — Scanned from DE
Effective URL: https://www.rybelsus.com/terms-and-conditions.html?utm_medium=email&utm_source=RTE&utm_campaign=successfulstarts&utm_cont...
Submission: On November 20 via manual from US — Scanned from DE
Form analysis 1 forms found in the DOM
<form class="cope-core-modal-content" id="gatedEntryForm" data-parsley-validate="" novalidate="">
<div class="cope-core-modal-buttons">
<button class="cope-core-button cope-core-button-style-primary cope-core-button-type-med" data-modal-trigger-close=""><span>Back</span></button>
<a class="cope-core-button cope-core-button-style-primary cope-core-button-type-med" data-exit-link="" href="#"><span>Access
Resources</span>
</a>
</div>
</form>Text Content
Important Safety Information Prescribing Information Medication Guide En Español
Healthcare Professionals Site
En Español
Why RYBELSUS®?
* Why RYBELSUS®?
* RYBELSUS® Results
* RYBELSUS® vs Other Diabetes Pills
* How RYBELSUS® Works
* Real RYBELSUS® Stories
Taking RYBELSUS®
* Taking RYBELSUS®
* How to Start RYBELSUS®
* What to Expect With RYBELSUS®
Savings & Support
FAQs
About Type 2 Diabetes
* About Type 2 Diabetes
* What Is Type 2 Diabetes?
* Type 2 Diabetes Lifestyle Tips
Search
Important Safety Information Prescribing Information Medication Guide En Español
Healthcare Professionals Site
Menu
Save on RYBELSUS®
RYBELSUS® Support Programs
Questions?
I can help
Please tell me what you're looking for
Save on RYBELSUS®
RYBELSUS® Support Programs
Questions?
I can help
TERMS AND CONDITIONS OF USE
Please read these terms and conditions carefully. By texting “AGREE” back, you
affirm that you are a US resident, 18 years of age or older, and expressly
consent to receive nonmarketing and marketing text messages from Novo Nordisk or
its partners in connection with Novo Nordisk’s Discover RYBELSUS® Program (the
“DISCOVER RYBELSUS® PROGRAM”), a text-based program to help individuals learn
more about the benefits of RYBELSUS® and how it works, and the RYBELSUS® Connect
Program (the “RYBELSUS® CONNECT PROGRAM”), a text-based patient support program
to help patients start and stay on RYBELSUS® (collectively, the “PROGRAMS”).
PLEASE NOTE THAT ALL LANGUAGE APPLIES EQUALLY TO THE PROGRAMS UNLESS OTHERWISE
DESIGNATED. Your consent to receive marketing messages is not required for the
receipt of goods or services from Novo Nordisk.
By participating in these SMS text messaging programs, you also agree to be
bound by the PROGRAMS’ Full Mobile Terms and Conditions of Use and the Novo
Nordisk Privacy Statement. For more information about data use and collection,
please read the most recent version of Novo Nordisk’s Privacy Statement.
The PROGRAMS' Full Mobile Terms and Conditions of Use:
* Express Consent. As stated above, by texting “AGREE” back, I affirm that I am
a US resident, 18 years of age or older, and expressly consent to receive
nonmarketing and marketing text messages (SMS) and texts with images (MMS)
from Novo Nordisk or its partners in connection with the PROGRAMS. I
understand that these messages may be made with an auto-dialer to my
telephone number and that my consent to receive marketing text messages is
not required for the receipt of goods or services from Novo Nordisk. These
messages may be sent from any of these phone numbers:
Longcode(s):
(609) 566-9350, (609) 631-3113, and (609) 400-4339
Shortcode(s):
44535 (To learn more about the DISCOVER RYBELSUS® PROGRAM)
21848 (For the RYBELSUS® CONNECT PROGRAM and all opt-out requests)
* Message Frequency. The PROGRAMS’ message frequency will vary depending on
your individual selections, but if enrolled in all features of the PROGRAMS,
you may receive up to approximately 24 text messages per week from Novo
Nordisk or its partners in connection with the PROGRAM. Please be aware that
Novo Nordisk brands and services may have separate text messaging programs.
The total number of text messages you receive from Novo Nordisk or its
partners, therefore, may vary based on the number of Novo Nordisk text
messaging programs for which you sign-up to receive messages.
* Cost. You will not be charged any fee from Novo Nordisk or its partners in
connection with the PROGRAMS to receive nonmarketing or marketing text
messages. However, Novo Nordisk encourages you to check with your mobile
service provider to see what other message and data rates may apply,
including any applicable roaming charges.
* Supported Carriers. The following US carriers are supported:
* Major Carriers: AT&T, Verizon Wireless, Sprint, and T-Mobile USA.
* Minor Carriers: Aio Wireless, Alaska Communications Systems (ACS),
Appalachian Wireless (EKN), Bluegrass Cellular, Boost Mobile, Carolina West
Wireless, CellCom, Cellular One of East Central IL (ECIT), Cellular One of
Northeast Arizona, Cellular One of Northeast Pennsylvania, Chariton Valley
Cellular, Cricket, Coral Wireless (MobiPCS), Cross, C-Spire (CellSouth),
Duet IP (Maximum Communications New Core Wireless), Element Mobile (Flat
Wireless), Epic Touch (Elkhart Telephone), GCI, Golden State, Google Voice,
Hawkeye (Chat Mobility), Hawkeye (NW Missouri), Illinois Valley Cellular,
Inland Cellular, iWireless (Iowa Wireless), Keystone Wireless (Immix
Wireless/PC Man), Metro PCS, Mosaic (Consolidated or CTC Telecom), MTA
Communications, MTPCS (Cellular One Nation), Nex-Tech Wireless, Panhandle
Communications, Peoples Wireless, Pine Cellular, Pioneer, RINA, Sagebrush
Cellular (Nemont), SI Wireless/Mobile Nation, Simmetry (TMP Corporation),
SouthernLinc, SRT Wireless, Thumb Cellular, Union Wireless, United
Wireless, U.S. Cellular, Viaero Wireless, Virgin Mobile, and West Central
(WCC or 5 Star Wireless).
* Opt-Out Options.
* RYBELSUS® CONNECT PROGRAM TEXT OPT-OUT.
* You may always opt-out of receiving text messages from Novo Nordisk or
its partners in relation to the RYBELSUS® CONNECT PROGRAM at any time by
sending a reply text stating “STOP,” texting “STOP” to 21848, or visiting
www.rc-optout.carespeak.com.
* Those enrolled in the RYBELSUS® CONNECT PROGRAM may also opt-in to
receive daily medicine reminders, refill reminders, and motivational and
support messages (“Optional Messages”). You may opt-out of receiving
these Optional Messages by following the below instructions.
* To stop receiving daily medicine reminders only, either send a reply
text stating “END,” or text “END” to 21848 to stop receiving medicine
reminders only.
* To stop receiving refill reminders and revoke your consent to share
your personal health information (as detailed in the HIPAA Waiver
located at https://mhm.carespeak.com/rybelsusconnect/waiver.html) only,
either send a reply text stating “REVOKE,” or text “REVOKE” to 21848 to
stop receiving the refill reminders only. Please know that once you
opt-out of refill reminders, you cannot opt back in to receive them
again.
* To stop receiving motivational messages only through the PROGRAMS,
either send a reply text stating “GRATEFULOFF,” or text “GRATEFULOFF”
to 21848 to stop receiving motivational messages only.
* You will receive a confirmation of your opt-out of that text messaging
program. Please note that this will only opt you out of the Optional
Message(s). As explained above, you understand that you can quit the
PROGRAM and stop receiving all text messages at any time by texting
back STOP. This will also stop any additional data collection. You also
will remain opted-in to other Novo Nordisk text and email messaging
programs for which you have enrolled, if enrolled.
* RYBELSUS® CONNECT PROGRAM WEBSITE OPT-OUT.
* In addition to opting-out of the RYBELSUS® CONNECT PROGRAM as set forth
above, you may also choose to stop receiving all text messages related to
the PROGRAM by visiting www.rc-optout.carespeak.com and entering your
cell phone number into the field provided there. Please note that by
opting-out via the website you will no longer receive any text messages
from the RYBELSUS® CONNECT PROGRAM. You will remain opted into other Novo
Nordisk text or other email messaging programs for which you have
enrolled.
* DISCOVER RYBELSUS® PROGRAM TEXT OPT-OUT.
* You may always opt-out of receiving text messages from Novo Nordisk or
its partners in relation to the DISCOVER RYBELSUS® PROGRAM at any time by
sending a reply text stating “STOP,” texting “STOP” to 44535.
* If you remain in the DISCOVER RYBELSUS® PROGRAM more than 35 days after
you complete your registration, you will automatically be opted out.
* Your Mobile Telephone Number. You represent that you are the account holder
for the mobile telephone number and you opt-in to receive text messages for
the PROGRAMS.
* Eligibility. To receive text messages or calls for the PROGRAMS, you must be
a resident of the US and 18 years of age or older. Novo Nordisk reserves the
right to require you to prove that you are at least 18 years of age.
* Access or Delivery to Mobile Network is Not Guaranteed. Delivery of
information and content to a mobile device is not guaranteed and may fail due
to a variety of circumstances or conditions. Alerts sent via text message may
not be delivered if the mobile phone is not in range of a transmission site
or if sufficient network capacity is not available at a particular time. Even
within a coverage area, factors beyond the control of the wireless carrier
may interfere with message delivery, including the customer's equipment,
terrain, proximity to buildings, foliage, and weather. Novo Nordisk will not
be held responsible for any delays in the receipt of any text messages as
delivery is subject to effective transmission from your mobile service
provider or network operator. You understand and acknowledge that network
services, including but not limited to mobile network services, are outside
of Novo Nordisk’s control, and Novo Nordisk is not responsible or liable for
issues arising from them.
* Privacy & Security.
* Since Novo Nordisk appreciates the value of your private personal health
information, Novo Nordisk wants you to understand that it cannot guarantee
the security of any personal health information transmitted via SMS text
message. SMS text messages are not encrypted or protected. These
communications and, possibly the content, may be stored on servers where
mobile carrier employees, governments, or other unknown third parties might
be able to view or access them.
* Novo Nordisk understands and values the importance of your privacy. Please
be aware that the data obtained from you in connection with this SMS
message service may, among other things, include your cell phone number,
carrier name, and message date, time, and content. We may use this
information to contact you and to provide the services you request from us.
In addition, your responses to any survey questions in these PROGRAMS will
be combined with the responses from other participants in these PROGRAMS
and shared with Novo Nordisk and the PROGRAMS’ partners. However, the
information shared with Novo Nordisk and the PROGRAMS’ partners will not
include your name, date of birth, or cell phone number or cell phone
carrier. For more information on how we collect and use your information,
please read our full Privacy Statement. If you opt out (as explained above)
from receiving text messages from the PROGRAMS, any future data collection
from you will end. You also understand that a significant portion of the
PROGRAMS is conducted via text messaging. These text messages may contain
health information. Standard text messaging is not encrypted, and a third
party could read these messages.
* Terms of Use of PROGRAMS. These PROGRAMS do not substitute medical advice
from your health care provider. You will have to contact him or her directly
about issues, questions, or concerns. (See NOT MEDICAL ADVICE below.) You
further understand that these PROGRAMS are not a means to communicate product
issues or negative side effects to Novo Nordisk. You are encouraged to report
negative side effects of prescription drugs to the FDA at
www.fda.gov/medwatch or by phone at 1-800-FDA-1088. Novo Nordisk is not
responsible for monitoring or recording text messages that may constitute an
issue or negative side effect. However, if you are using a Novo Nordisk
Product as treatment, and some of your entered responses can be interpreted
as a side effect of the medication, Novo Nordisk reserves the right to
contact you for more information by phone or written communication. For
additional information about your medication, please call Novo Nordisk
Customer Care at 1-833-457-7455.
* NOT MEDICAL ADVICE. The PROGRAMS include text message support to help you
learn more about and/or start on RYBELSUS®. OUR CONTENT AND COMMUNICATIONS
ARE NOT INTENDED TO BE A REPLACEMENT OR SUBSTITUTE FOR PROFESSIONAL MEDICAL
ADVICE. THE CONTENT AND COMMUNICATIONS DO NOT CONSTITUTE MEDICAL ADVICE,
DIAGNOSIS, OR TREATMENT. YOU ACKNOWLEDGE AND UNDERSTAND THAT YOU WILL SEEK
THE ADVICE OF A PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROVIDER WITH ANY
QUESTIONS THAT ARISE REGARDING ANY MEDICAL CONDITION. YOU ACKNOWLEDGE THAT
ALL INFORMATION AND GUIDANCE PROVIDED BY YOU IS SOLELY AT YOUR OWN RISK. You
understand that Novo Nordisk does not endorse any particular physician or
health care provider for the treatment of any specific medical condition.
* Changes to Terms and Conditions of Use. Novo Nordisk may revise, modify, or
amend the PROGRAM’s Mobile Terms and Conditions of Use for text messages and
calls at any time. Any such revision, modification, or amendment will take
effect when such changes are circulated to PROGRAM participants via text
message. Novo Nordisk encourages you to thoroughly review any changes to
Terms and Conditions of Use should you receive them.
* Termination of Text Messaging. Novo Nordisk may suspend or terminate your
receipt of Novo Nordisk text messages if Novo Nordisk believes you are in
breach of these Mobile Terms and Conditions for SMS Messages. Your receipt of
Novo Nordisk text messages is also subject to termination in the event that
your mobile telephone service terminates or lapses. Novo Nordisk reserves the
right to modify or discontinue, temporarily or permanently, all or any part
of Novo Nordisk text messages, with or without notice. You assume sole
responsibility for the proper use and scheduling of any medications,
treatments, and procedures related to the patient's health care and disease
management. Novo Nordisk assumes no responsibility for the accuracy or
appropriateness of any information entered by you.
Indication and Important Safety Information
READ MORE COLLAPSE
WHAT IS RYBELSUS®?
RYBELSUS® (semaglutide) tablets 7 mg or 14 mg is a prescription medicine used
along with diet and exercise to improve blood sugar (glucose) in adults with
type 2 diabetes.
* RYBELSUS® is not recommended as the first choice of medicine for treating
diabetes
* It is not known if RYBELSUS® can be used in people who have had pancreatitis
* RYBELSUS® is not for use in people with type 1 diabetes
* It is not known if RYBELSUS® is safe and effective for use in children under
18 years of age
Scroll to "What is RYBELSUS®?"
IMPORTANT SAFETY INFORMATION
WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT RYBELSUS®?
RYBELSUS® may cause serious side effects, including:
* Possible thyroid tumors, including cancer. Tell your healthcare provider if
you get a lump or swelling in your neck, hoarseness, trouble swallowing, or
shortness of breath. These may be symptoms of thyroid cancer. In studies with
rodents, RYBELSUS® and medicines that work like RYBELSUS® caused thyroid
tumors, including thyroid cancer. It is not known if RYBELSUS® will cause
thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma
(MTC) in people
Do not use RYBELSUS® if:
* you or any of your family have ever had MTC, or if you have an endocrine
system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
* you have had a serious allergic reaction to semaglutide or any of the
ingredients in RYBELSUS®. See symptoms of serious allergic reaction in "What
are the possible side effects of RYBELSUS®?"
Scroll to ISI
WHAT IS RYBELSUS®?
RYBELSUS® (semaglutide) tablets 7 mg or 14 mg is a prescription medicine used
along with diet and exercise to improve blood sugar (glucose) in adults with
type 2 diabetes.
* RYBELSUS® is not recommended as the first choice of medicine for treating
diabetes
* It is not known if RYBELSUS® can be used in people who have had pancreatitis
* RYBELSUS® is not for use in people with type 1 diabetes
* It is not known if RYBELSUS® is safe and effective for use in children under
18 years of age
IMPORTANT SAFETY INFORMATION (CONT'D)
Before using RYBELSUS®, tell your healthcare provider if you have any other
medical conditions, including if you:
* have or have had problems with your pancreas or kidneys
* have a history of vision problems related to your diabetes
* are pregnant or plan to become pregnant. It is not known if RYBELSUS® will
harm your unborn baby. You should stop using RYBELSUS® 2 months before you
plan to become pregnant. Talk to your healthcare provider about the best way
to control your blood sugar if you plan to become pregnant or while you are
pregnant
* are breastfeeding or plan to breastfeed. Breastfeeding is not recommended
during treatment with RYBELSUS®
Tell your healthcare provider about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal supplements.
RYBELSUS® may affect the way some medicines work and some medicines may affect
the way RYBELSUS® works.
HOW SHOULD I TAKE RYBELSUS®?
* Take RYBELSUS® exactly as your healthcare provider tells you to
* Take RYBELSUS® by mouth on an empty stomach when you first wake up with a sip
of plain water (no more than 4 ounces)
* Do not split, crush, or chew. Swallow RYBELSUS® whole
* After 30 minutes, you can eat, drink, or take other oral medicines
* If you miss a dose of RYBELSUS®, skip the missed dose and go back to your
regular schedule
WHAT ARE THE POSSIBLE SIDE EFFECTS OF RYBELSUS®?
RYBELSUS® may cause serious side effects, including:
* inflammation of your pancreas (pancreatitis). Stop using RYBELSUS® and call
your healthcare provider right away if you have severe pain in your stomach
area (abdomen) that will not go away, with or without vomiting. You may feel
the pain from your abdomen to your back
* changes in vision. Tell your healthcare provider if you have changes in
vision during treatment with RYBELSUS®
* low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be
higher if you use RYBELSUS® with another medicine that can cause low blood
sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood
sugar may include: dizziness or lightheadedness, blurred vision, anxiety,
irritability or mood changes, sweating, slurred speech, hunger, confusion or
drowsiness, shakiness, weakness, headache, fast heartbeat, and feeling
jittery
* kidney problems (kidney failure). In people who have kidney problems,
diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration),
which may cause kidney problems to get worse. It is important for you to
drink fluids to help reduce your chance of dehydration
* serious allergic reactions. Stop using RYBELSUS® and get medical help right
away, if you have any symptoms of a serious allergic reaction, including
swelling of your face, lips, tongue, or throat; problems breathing or
swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid
heartbeat
* gallbladder problems. Gallbladder problems have happened in some people who
take RYBELSUS®. Tell your healthcare provider right away if you get symptoms
of gallbladder problems, which may include: pain in your upper stomach
(abdomen), yellowing of skin or eyes (jaundice), fever, and clay-colored
stools
The most common side effects of RYBELSUS® may include nausea, stomach
(abdominal) pain, diarrhea, decreased appetite, vomiting, and constipation.
Nausea, vomiting, and diarrhea are most common when you first start RYBELSUS®.
Please see Prescribing Information and Medication Guide for RYBELSUS®.
RYBELSUS® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
IMPORTANT SAFETY INFORMATION
WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT RYBELSUS®?
RYBELSUS® may cause serious side effects, including:
* Possible thyroid tumors, including cancer. Tell your healthcare provider if
you get a lump or swelling in your neck, hoarseness, trouble swallowing, or
shortness of breath. These may be symptoms of thyroid cancer. In studies with
rodents, RYBELSUS® and medicines that work like RYBELSUS® caused thyroid
tumors, including thyroid cancer. It is not known if RYBELSUS® will cause
thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma
(MTC) in people
Do not use RYBELSUS® if:
* you or any of your family have ever had MTC, or if you have an endocrine
system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
* you have had a serious allergic reaction to semaglutide or any of the
ingredients in RYBELSUS®. See symptoms of serious allergic reaction in "What
are the possible side effects of RYBELSUS®?"
WHAT IS RYBELSUS®?
RYBELSUS® (semaglutide) tablets 7 mg or 14 mg is a prescription medicine used
along with diet and exercise to improve blood sugar (glucose) in adults with
type 2 diabetes.
* RYBELSUS® is not recommended as the first choice of medicine for treating
diabetes
* It is not known if RYBELSUS® can be used in people who have had pancreatitis
* RYBELSUS® is not for use in people with type 1 diabetes
* It is not known if RYBELSUS® is safe and effective for use in children under
18 years of age
WHAT IS RYBELSUS®?
RYBELSUS® (semaglutide) tablets 7 mg or 14 mg is a prescription medicine used
along with diet and exercise to improve blood sugar (glucose) in adults with
type 2 diabetes.
* RYBELSUS® is not recommended as the first choice of medicine for treating
diabetes
* It is not known if RYBELSUS® can be used in people who have had pancreatitis
* RYBELSUS® is not for use in people with type 1 diabetes
* It is not known if RYBELSUS® is safe and effective for use in children under
18 years of age
IMPORTANT SAFETY INFORMATION
Before using RYBELSUS®, tell your healthcare provider if you have any other
medical conditions, including if you:
* have or have had problems with your pancreas or kidneys
* have a history of vision problems related to your diabetes
* are pregnant or plan to become pregnant. It is not known if RYBELSUS® will
harm your unborn baby. You should stop using RYBELSUS® 2 months before you
plan to become pregnant. Talk to your healthcare provider about the best way
to control your blood sugar if you plan to become pregnant or while you are
pregnant
* are breastfeeding or plan to breastfeed. Breastfeeding is not recommended
during treatment with RYBELSUS®
Tell your healthcare provider about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal supplements.
RYBELSUS® may affect the way some medicines work and some medicines may affect
the way RYBELSUS® works.
HOW SHOULD I TAKE RYBELSUS®?
* Take RYBELSUS® exactly as your healthcare provider tells you to
* Take RYBELSUS® by mouth on an empty stomach when you first wake up with a sip
of plain water (no more than 4 ounces)
* Do not split, crush, or chew. Swallow RYBELSUS® whole
* After 30 minutes, you can eat, drink, or take other oral medicines
* If you miss a dose of RYBELSUS®, skip the missed dose and go back to your
regular schedule
WHAT ARE THE POSSIBLE SIDE EFFECTS OF RYBELSUS®?
RYBELSUS® may cause serious side effects, including:
* inflammation of your pancreas (pancreatitis). Stop using RYBELSUS® and call
your healthcare provider right away if you have severe pain in your stomach
area (abdomen) that will not go away, with or without vomiting. You may feel
the pain from your abdomen to your back
* changes in vision. Tell your healthcare provider if you have changes in
vision during treatment with RYBELSUS®
* low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be
higher if you use RYBELSUS® with another medicine that can cause low blood
sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood
sugar may include: dizziness or lightheadedness, blurred vision, anxiety,
irritability or mood changes, sweating, slurred speech, hunger, confusion or
drowsiness, shakiness, weakness, headache, fast heartbeat, and feeling
jittery
* kidney problems (kidney failure). In people who have kidney problems,
diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration),
which may cause kidney problems to get worse. It is important for you to
drink fluids to help reduce your chance of dehydration
* serious allergic reactions. Stop using RYBELSUS® and get medical help right
away, if you have any symptoms of a serious allergic reaction, including
swelling of your face, lips, tongue, or throat; problems breathing or
swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid
heartbeat
* gallbladder problems. Gallbladder problems have happened in some people who
take RYBELSUS®. Tell your healthcare provider right away if you get symptoms
of gallbladder problems, which may include: pain in your upper stomach
(abdomen), yellowing of skin or eyes (jaundice), fever, and clay-colored
stools
The most common side effects of RYBELSUS® may include nausea, stomach
(abdominal) pain, diarrhea, decreased appetite, vomiting, and constipation.
Nausea, vomiting, and diarrhea are most common when you first start RYBELSUS®.
Please see Prescribing Information and Medication Guide for RYBELSUS®.
RYBELSUS® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
* Privacy Notice
* Cookie Policy
* Privacy Request
* About Novo Nordisk
* Site Map
* Contact Us
RYBELSUS® is a registered trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their
respective owners.
© 2023 Novo Nordisk All rights reserved. US22RYB01079 April 2023
Continue Return to Site
Continue Return to Site
Back Access Resources
Return to Previous Page
Novo Nordisk values your privacy and is committed to the transparent use of your
personal information. We use cookies to improve the functionality and
performance of this site, other cookies are used to remember your preferences or
to share relevant content with you. By clicking “Accept All Cookies,” you
consent to our recommended use of cookies in accordance with our Cookie Policy
and Privacy Policy. You can also “Reject All” which leaves only strictly
necessary cookies to enable website functionality. You can always review,
modify, or revoke your consent by clicking “Customize Cookies.”
Accept All Cookies
Reject All
Customize Cookies
COOKIE PREFERENCE CENTER
* YOUR PRIVACY
* STRICTLY NECESSARY COOKIES
* FUNCTIONALITY COOKIES
* PERFORMANCE COOKIES
* ADVERTISING COOKIES
YOUR PRIVACY
When you visit any website, it may store or retrieve information on your
browser, often in the form of cookies. This information might be about your
preferences or your device and is mostly used to make the site work as you
expect it to. The information does not identify you, but it can give you a more
personalized web experience. Because we respect your right to privacy, you can
choose whether to allow or disallow certain categories of cookies on Novo
Nordisk websites. Click on the different category headings to the left to find
out more about these cookies do and change which cookies categories you allow.
However, understand that blocking some types of cookies may impact your
experience of the site and the services we are able to offer.
More information
STRICTLY NECESSARY COOKIES
Always Active
These cookies are required for the operation of our website and cannot be
switched off without impairing the functionality of the site. Strictly necessary
cookies are set to respond to actions you take, including navigating our site
and using its basics features. These cookies do not store any Personal
Information.
FUNCTIONALITY COOKIES
Functionality Cookies Active
Allow our websites to remember your user name, language preference, or
geographic region. This information is used to provide a personalised experience
and to make the website easier to use. If you don’t allow these cookies, then
some or all features may not function.
PERFORMANCE COOKIES
Performance Cookies Active
Collect information about your use of our website, e.g. page visits or error
messages. This information is aggregated and anonymized and used to improve our
website. If you don’t allow these cookies, we won’t know when you have visited
our website and won’t be able to monitor its performance.
ADVERTISING COOKIES
Advertising Cookies Active
Allow us to display advertising we think is relevant to you. We build profiles
based on your browsing history, which we share with our advertising partners to
show you relevant advertisements on other sites. If you don’t allow these
cookies you will still receive advertising, but it will be less relevant.
Back Button
COOKIE LIST
Filter Button
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label
Clear
checkbox label label
Apply Cancel
Confirm My Choices
Reject All Allow All